Melior Discovery

Website Links

Description

Andrew G. Reaume, PhD, MBA President and CEO, Co-Founder Dr. Reaume was previously a Senior Business Analyst at Pfizer, Incorporated in the department of Genomics and Proteomic Sciences. There he spearheaded an initiative to create a platform for comprehensively characterizing (phenotyping) genetically modified mice and ran the collaboration involving a third party partnership to build it. This effort involved working closely with scientists throughout the global Pfizer organization, business development professionals, information technology specialists as well as the scientists and business development professionals at the partner company. From 1993 to 1999, Dr. Reaume worked as a research scientist at Cephalon where he was principally involved in creating animal models of neurodegenerative disease. During this time Dr. Reaume worked closely on a number of projects with Dr. Saporito, co-founder of Melior. In addition to Dr. Reaume's research activities at Cephalon, he identified and helped coordinate three in-licensing opportunities. In 2003, he received his MBA from the Wharton School where he graduated with honors in Entrepreneurial Management. He received his PhD in genetics from the University of Connecticut in 1990. Michael S. Saporito, PhD Vice President of Research, Co-Founder Dr. Saporito has spent the last 15 years in positions of increasing responsibility in the pharmaceutical industry. From 1991 to 2002, Dr. Saporito was Scientist at Cephalon Incorporated in the Departments of Neurobiology and Pharmacology. At Cephalon, Dr. Saporito was the lead pharmacologist in the discovery of CEP-1347, a neuroprotective kinase inhibitor that reached Phase III clinical trials for Parkinson's disease. While at Cephalon, Dr. Saporito and Dr. Reaume collaborated on a number of projects involving molecular and cellular mechanisms of neurodegeneration. From 2002 to 2004, Dr. Saporito was Group Leader in Biology at Locus Pharmaceuticals, a computational drug design company. In this role he led various preclinical programs targeting oncological, inflammatory and neurological therapeutic endpoints. Dr. Saporito has extensive experience with a wide variety of animal models of diseases encompassing inflammation, metabolic disease, neurological disorders and cancer. Dr. Saporito received his Ph.D. in Pharmacology from the Philadelphia College of Pharmacy and Science (currently The University of Sciences of Philadelphia) and continued his postdoctoral studies at UMDNJ-Robert Wood Johnson Medical School under the direction of Dr. Richard Heikkila. Jeffrey Handler, PhD, DABT, MBA Vice President of Development Dr. Handler was previously the Vice President of Research and Development for Dermik Laboratories, the dermatology unit of Sanofi-Aventis Pharmaceuticals. In this role he was responsible for all aspects of drug identification and development for dermatological use, including oversight of early compound assessment, analytical and formulation work, preclinical and clinical studies, regulatory activities and technical support of marketed products. Dr.

Products & services

Similar companies nearby